TESARO is an oncology-focused biopharmaceutical company dedicated to improving the lives of cancer patients. The Company intends to leverage the experience and competencies of its management team to identify, acquire and develop promising drug candidates; and to commercialize safer and more effective products for the treatment and support of cancer patients.
TESARO is developing rolapitant, a potent, selective neurokinin-1 receptor antagonist that has completed Phase 2 clinical testing for the prevention of chemotherapy-induced nausea and vomiting, and is advancing its ALK inhibitor program for oncology indications.
Company Growth (employees)
Type
Public
HQ
Waltham, US
Founded
2010
Size (employees)
446 (est)
TESARO was founded in 2010 and is headquartered in Waltham, US

TESARO Office Locations

TESARO has an office in Waltham
Waltham, US (HQ)
3300 1000 Winter St

TESARO Data and Metrics

TESARO Financial Metrics

TESARO's revenue was reported to be $3.1 m in Q1, 2017
USD

Revenue (Q1, 2017)

3.1 m

Net income (Q1, 2017)

(136.7 m)

EBIT (Q1, 2017)

(133.2 m)

Market capitalization (21-Sep-2017)

6.4 b

Cash (31-Mar-2017)

672.2 m
TESARO's current market capitalization is $6.4 b.
USDFY, 2013FY, 2014FY, 2015FY, 2016

Revenue

317 k44.8 m

Revenue growth, %

14040%

R&D expense

235.1 m

General and administrative expense

158.6 m
USDQ2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017

Revenue

307 k36.6 m3.7 m3.1 m

R&D expense

30.6 m29.9 m33.5 m38.9 m40.1 m52.6 m50.1 m60.8 m66.1 m

General and administrative expense

5.6 m6.3 m11.2 m16.8 m22.8 m30 m36.2 m37.7 m69.3 m

Operating expense total

36.2 m36.2 m44.8 m55.7 m62.8 m82.7 m86.4 m98.5 m135.4 m
USDFY, 2013FY, 2014FY, 2015FY, 2016

Cash

130.3 m256.9 m230.1 m785.9 m

Accounts Receivable

679 k5.3 m

Inventories

1.1 m14.7 m

Current Assets

134.3 m258.6 m236.5 m814.8 m
USDQ2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017

Cash

151.1 m295.9 m399.1 m354.4 m302.5 m314.5 m320.2 m647.3 m672.2 m

Accounts Receivable

1.1 m1.1 m510 k3.2 m6.1 m

Inventories

476 k6 m8.4 m12.2 m15.6 m

Current Assets

154.1 m297.7 m401.3 m357.2 m308.5 m325.7 m337.8 m670.1 m707.6 m
USDFY, 2013FY, 2014FY, 2015FY, 2016

Net Income

(92.4 m)(171 m)(251.4 m)(387.5 m)

Depreciation and Amortization

179 k349 k1 m3.1 m

Accounts Receivable

(679 k)5.3 m

Inventories

(1.1 m)14.7 m
USDQ2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017

Net Income

(37.1 m)(36.2 m)(48.5 m)(60.6 m)(66.6 m)(90.8 m)(58.4 m)(101.2 m)(136.7 m)

Accounts Receivable

1.1 m1.1 m510 k3.2 m6.1 m

Inventories

476 k6 m8.4 m12.2 m15.6 m

Accounts Payable

2.8 m4.1 m5.7 m9.6 m5.6 m12.3 m14 m3.3 m10.3 m
USDY, 2017

Revenue/Employee

6.9 k

Financial Leverage

1.5 x
Show all financial metrics

TESARO Operating Metrics

FY, 2016

Products

2

Countries

7

Patent Portfolios

3
Show all operating metrics

TESARO Market Value History

Traffic Overview of TESARO

TESARO Online and Social Media Presence

TESARO News and Updates

This Biotech’s Stock Just Doubled and It’s Bad News for Sanofi

Tesaro shares skyrocketed on data about its ovarian cancer drug.

TESARO Company Life and Culture

You may also be interested in